PN summer web series kicks off in July! Learn more

Anti-MAG Peripheral Neuropathy

FPN Funds IMAGiNe Study for anti-MAG Research

FPN Funds IMAGiNe Study for anti-MAG Research

Through the generosity of our donors, the Foundation for Peripheral Neuropathy (FPN) was able to support the IMAGiNe study with a $165,000 research grant to fund new patient enrollment for anti-MAG neuropathy. $90,000 of these funds were spent in 2022, which resulted in over 150 new patients enrolling in the study. In 2023, an additional $24,750 was spent, …

FPN Funds IMAGiNe Study for anti-MAG Research Read More »

Anti-MAG neuropathy

TREATING ANTI-MAG PN – A LOOK BACK AND WHAT MAY BE COMING

Introduction to Anti-MAG Neuropathy Anti-MAG neuropathy refers to a rare auto-immune associated cause of peripheral neuropathy (PN). In this case, the person’s own immune system (specifically, the IgM monoclonal antibodies) attack nerve cells required for a healthy peripheral nervous system – resulting in a slowly progressive and debilitating condition. Patients often experience loss of mobility, …

TREATING ANTI-MAG PN – A LOOK BACK AND WHAT MAY BE COMING Read More »

Study Protocol on IgM Anti-Mag Neuropathy Released

The Foundation for Peripheral Neuropathy (FPN) is pleased that the IMAGiNe study protocol has been approved for publication in the Journal of the Peripheral Nervous System. The focus of this international study is a rare autoimmune cause of PN. It is identified by high levels of the IgM protein in the blood of affected patients, …

Study Protocol on IgM Anti-Mag Neuropathy Released Read More »

FPN Funding Contributes $90,000 to IMAGiNe Study for anti-MAG Research

Through the generosity of our donors, we’re able to support the IMAGiNe study with a $150,000 research grant to fund new patient enrollment. $90,000 of these funds, spent in 2022, resulted in over 150 new patients enrolling in the study. The IMAGiNe Study The IMAGiNe study is an international research collaborative focused on patients with …

FPN Funding Contributes $90,000 to IMAGiNe Study for anti-MAG Research Read More »

Anti-MAG Peripheral Neuropathy: Q&A

Anti-MAG peripheral neuropathy (Immunoglobulin M(IgM) Anti-Myelin Associated Glycoprotein Peripheral Neuropathy) is a rare autoimmune variety of peripheral neuropathy. In this type of PN, a person’s own immune system attacks cells that are specific in maintaining a healthy peripheral nervous system. As these cells are destroyed by antibodies, they lose function and create problems in both …

Anti-MAG Peripheral Neuropathy: Q&A Read More »

CLINICAL HIGHLIGHTS: PNS Meeting 2022

The Peripheral Nerve Society Annual Meeting was held in Miami in May 2022. The Foundation for Peripheral Neuropathy is pleased to be able to provide PNS Meeting 2022 highlights, summarizing some of the clinical studies presented at the conference. Study teams reported on natural history studies and (clinical) intervention trials for peripheral neuropathies who concluded …

CLINICAL HIGHLIGHTS: PNS Meeting 2022 Read More »

Research Study Back on Track!

Following over a year’s delay due to the COVID-19 pandemic, the IMAGiNe Study is finally back on track! The IMAGiNe Study (Immunoglobulin M(IgM)-Anti-myelin-associated-glycoprotein (MAG) Peripheral Neuropathy Study) is a research program that aims to create a standardized database and biobank to be used for the research and analysis of Anti-MAG peripheral neuropathy. The goal is to be able to …

Research Study Back on Track! Read More »

IMAGiNe Study on anti-MAG IgM paraprotein-associated peripheral neuropathy expanding in the U.S.

The Foundation for Peripheral Neuropathy (FPN) is pleased to announce a new partnership to further research on anti-MAG IgM paraprotein-associated peripheral neuropathy. FPN will be partnering with the IMAGiNe study, a global research collaborative focusing on anti-MAG and IgM paraprotein-associated peripheral neuropathy. Thanks to a donation from the Atlantic Philanthropies Director/Employee Designated Gift Fund, FPN …

IMAGiNe Study on anti-MAG IgM paraprotein-associated peripheral neuropathy expanding in the U.S. Read More »